麻豆AV

Abstract:

听

Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor, and the active pharmaceutical ingredient of Sunlenca庐. Three different approaches to stereochemical control of a key amine building block of lenacapavir were employed for clinical deliveries, culminating in a zinc catalyzed crystallization-induced dynamic resolution (CIDR) strategy. The CIDR process was further refined to improve process efficiency and scalability, and produces the target amine in 99.9% chiral purity.

听

听

听

听Bio:

Sara was born and raised in Saskatchewan, and received a BSc. from the University of Saskatchewan, completing an honours project in Prof. Dale Ward's group and spending summers working in Prof. David Sanders' lab. She joined Prof. Frederick West's group at the University of Alberta, completing her PhD thesis titled "Unconventional Substrates for the Nazarov and Imino-Nazarov Reactions" in 2012. She then joined Prof. Albert Padwa's group as a postdoc developing cascade stitching reactions of bis(diazo)compounds. Sara began her professional career as a process chemist at Gilead Alberta ULC in 2013, and has worked on numerous projects at all stages of drug development ranging from pre-clinical through approval over the past decade.